Healthcare needs systems that work for providers, for health plans, and most importantly, for patients. And that starts with designing not just for technology, but for the people who depend on it, people who need to trust it will work when it matters most. The post Healthcare IT Isn’t Broken — But How We Design…
This issue brief provides background on the GENEROUS model, examines the factors that will contribute to the model’s overall impact on Medicaid drug costs, and illustrates how savings will depend on model details that are confidential or uncertain at this time.
Bispecific antibodies are one of the hottest areas for drug research and dealmaking, and several of them were discussed this week during the annual J.P. Morgan Healthcare Conference in San Francisco. Takeda President, Research and Development, Andy Plump talked to MedCity News about what sets the Japanese pharma company’s newly licensed drug apart. The post…
Let’s be clear: The primary reason to be vaccinated against shingles is that two shots provide at least 90% protection against a painful, blistering disease that a third of Americans will suffer in their lifetimes, one that can cause lingering nerve pain and other nasty long-term consequences. The most important reason for older adults to…
Affordability, drug costs and AI will be top of mind for employers in 2026, according to Morgan Health CEO Dan Mendelson. The post Morgan Health: 5 Predictions for Employer-Sponsored Insurance in 2026 appeared first on MedCity News.
Regenstrief’s Joshua Vest, Ph.D., M.P.H., discusses potential advantages of using a predictive model to predict future need for health-related social services
This analysis examines PEPFAR spending and HIV viral suppression rates in 22 countries from 2018–2023 to help identify which investments most effectively drive HIV outcomes and inform future directions.
Nearly 1 in 4 Medicaid enrollees are eligible for the program because they are ages 65 and older or have a disability, and they have higher per-enrollee costs than other enrollees. Proposals to limit federal spending on Medicaid may create incentives for states to drop or reduce their eligibility or coverage for seniors and people…
If you rely on federal grants as your sole means of support, you’re tying your destiny to forces outside your control. There are other roads to success in health and medical research. By pursuing them, you might gain more freedom, fewer administrative hurdles, and the chance to save lives faster. The post Will the Entire…
Zarminali’s Series A round was led by Healthier Capital and included participation from General Catalyst and K2 HealthVentures. The post Zarminali Pediatrics Lands $110M to Reshape Pediatric Care appeared first on MedCity News.